Table 5. Contractile Profile of Isolated Right Ventricular Papillary Muscles.
| Group | Fdev (mN/mm2) | TTP (ms) | RT50 (ms) |
|---|---|---|---|
| Control | 14 ± 2 | 49 ± 1* | 23 ± 1* |
| T4 | 11 ± 1 | 41 ± 1 | 18 ± 1 |
| DMSO + T4 | 14 ± 2 | 38 ± 1 | 18 ± 1 |
| Sorafenib + T4 | 15 ± 4 | 44 ± 4 | 22 ± 2* |
| TadalafilIP + T4 | 12 ± 2 | 41 ± 1 | 17 ± 1 |
| TadalafilOr + T4 | 21 ± 3* | 41 ± 1 | 16 ± 0.4 |
| CMC + T4 | 24 ± 5* | 39 ± 1 | 17 ± 1 |
| MacitentanLD + T4 | 16 ± 3 | 39 ± 1 | 16 ± 1 |
| MacitentanHD + T4 | 19 ± 3 | 38 ± 1 | 16 ± 1 |
Fdev: isometric developed force, TTP: time to peak, RT50: 50% relaxation time, Control; n = 12, Thyroxin (T4); n = 15, Dimethyl sulfoxide (DMSO); N = 10, Sorafenib; n = 9, TadalafilIP (intraperitoneal, 1 mg/kg); n = 10, TadalafilOr (oral, 4 mg/kg); n = 8, carboxymethylcellulose (CMC); n = 8, MacitentanLD (Low dose: 30 mg/kg); n = 8, MacitentanHD (High dose: 100 mg/kg); n = 7.
*: indicates a significant change as revealed by one-way ANOVA followed by Dunnett Multiple Comparisons post-hoc test, comparing all groups to T4.